Sign up for the QMED & MD+DI Daily newsletter.
This Week Last Year in Medtech: May 21-27
See what Dexcom, LumiraDx, and Illumina were up to this time last year.
1 Min Read
Archive Holdings Inc. / The Image Bank via Getty Images
25 Most Attractive Medtech M&A Targets in 2022
These public medtech companies were identified as attractive for potential M&A based on products, growth, and margins. List does not account for valuations.
LabCorp Is Focusing on Skin Cancer with New Test
The Burlington, NC-based company’s melanoma test determines the level of expression of the lymphocyte-activation gene 3 (LAG-3).
What Would a Dexcom-Insulet Merger Look Like?
Dexcom is rumored to be in acquisition talks with Insulet. Such a deal would have a major impact on the competitive landscape for diabetes tech.
Apple Watch ECG Readings Plus AI Detect Weak Hearts
Mayo Clinic researchers developed the AI algorithm to interpret single-lead ECG tracings from an Apple Watch to more effectively identify patients who are living with a weak heart pump.
LumiraDx Scores CE Mark for Fast POC COVID-19 Test
The London-based company said the assay detects the presence of antigens in five minutes.
Illumina Obtains CDx Pan-Cancer Indication for TruSight Test
The test, which has CE mark, would be a companion diagnostic to Bayer’s Vitrakvi, a cancer treatment drug.
Stryker Launches EasyFuse Compression System
The Kalamazoo, MI-based company’s device is for high-demand foot and ankle applications.
Why Diversity in Medtech Matters
MedTech Color, a nonprofit organization formed in 2018, is making gains toward greater medtech diversity.
Medtronic to Spin Renal Business into New Company
Medtronic will co-own the new kidney device company with DaVita, each with equal equity stakes.
About the Author(s)
You May Also Like
